Sanofi-Aventis Eyes Summer Launch For Ambien CR
This article was originally published in The Pink Sheet Daily
Executive Summary
Discussions with FDA following an "approvable" letter for the sleep therapy have revolved around labeling for treatment duration, the company says. A summer launch would put Ambien CR's introduction several months behind that of Sepracor's Lunesta, which entered the insomnia market in early April.
You may also be interested in...
King Lowers Sonata Forecast, Citing Increased Competitive Activity
King takes $126.9 mil. charge in the second quarter related to Sonata; quarterly sales of the sleep aid are up due to inventory reductions.
King Lowers Sonata Forecast, Citing Increased Competitive Activity
King takes $126.9 mil. charge in the second quarter related to Sonata; quarterly sales of the sleep aid are up due to inventory reductions.
Takeda's Rozerem Will Not Be First-Line Competitor To Ambien, Sanofi Says
Rozerem (ramelteon) launch could open a new segment of sleep aid market; Sanofi-Aventis predicts the insomnia agent's different mechanism of action will prevent it from competing directly with Ambien. Company is readying launch of Ambien CR to counter increased competition.